Table 2.

Associations of all autosomal mCAs and mCAs subtypes with bladder cancer among 99,877 participants.

			HR (95% CI)
	Incident cases/N	Incidence rate (1/100 000)	Model 1	Model 2	Model 3
All autosomal mCAs -	147/97,265	13.1	1.00	1.00	1.00
All autosomal mCAs +	12/2612	41.1	2.60 (1.44, 4.69)	2.60 (1.44, 4.70)	2.60 (1.44, 4.70)
Non-expanded	6/1270	42.8	2.63 (1.16, 5.96)	2.64 (1.16, 6.00)	2.60 (1.14, 5.92)
Expanded	6/1342	39.5	2.57 (1.13, 5.83)	2.55 (1.13, 5.80)	2.59 (1.14, 5.89)
mCAs subtypes
Loss -	153/99,454	13.3	1.00	1.00	1.00
Loss +	6/423	133.6	6.75 (2.96, 15.37)	6.70 (2.93, 15.30)	6.68 (2.92, 15.30)
Non-expanded	1/61	148.9	7.78 (1.07, 56.38)	8.11 (1.12, 58.89)	8.96 (1.23, 65.28)
Expanded	5/362	130.9	6.57 (2.68, 16.14)	6.47 (2.63, 15.94)	6.35 (2.57, 15.70)
CN-LOH -	154/98,162	13.6	1.00	1.00	1.00
CN-LOH +	5/1715	25.8	1.73 (0.71, 4.24)	1.74 (0.71, 4.25)	1.76 (0.72, 4.30)
Non-expanded	4/789	45.5	2.87 (1.06, 7.78)	2.89 (1.07, 7.83)	2.83 (1.04, 7.67)
Expanded	1/926	9.5	0.67 (0.09, 4.80)	0.67 (0.09, 4.80)	0.70 (0.10, 5.02)

There were no bladder cancer cases among mosaic gain carriers. All multivariate models were stratified by age in the 5-year interval and 10 regions, and adjusted for sex and genotyping array (model 1), top 5 principal components, family history of cancer, and highest education (model 2), tobacco smoking, alcohol consumption, tea drinking, BMI, and PA (model 3).

HR hazard ratios, CI confidence interval, mCAs mosaic chromosomal alterations, CN-LOH copy-neutral loss of heterozygosity, BMI body mass index, PA physical activity